Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d fo...

متن کامل

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Paricalcitol was evaluated for the treatment of secondary hyperparathyroidism (SHPT) in a long-term, prospective, open-label study of 37 patients with end-stage renal failure resistant to intravenous calcitriol. All patients had an intact parathyroid hormone (iPTH) level of 600 pg/mL or greater before being converted from calcitriol to paricalcitol therapy. Paricalcitol therapy was initiated at...

متن کامل

Renal secondary hyperparathyroidism in dogs.

The parathyroid glands secrete parathyroid hormone (PTH), which is important for maintaining calcium homeostasis. Parathyroid gland hyperplasia and subsequent hyperparathyroidism can occur secondary to chronic renal failure in dogs, resulting in significant alterations in calcium metabolism. Renal secondary hyperparathyroidism is a complex, multifactorial syndrome that involves changes in circu...

متن کامل

[Renal osteodystrophy and secondary hyperparathyroidism].

High-turnover bone due to excess PTH is one of the main types of renal osteodystrophy. In addition to the classic stimuli of PTH secretion such as hypocalcemia and decreased production of active vitamin D, new mechanisms has been suggested. Furthermore, skeletal resistance to PTH, a classic stimulus of PTH secretion in uremia, has been recently revisited as an underlying abnormality.

متن کامل

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease

Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active vitamin D. Replacement with calcitriol, the active form of vitamin D, lowers PTH but often raise...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of the American Society of Nephrology

سال: 2014

ISSN: 1046-6673,1533-3450

DOI: 10.1681/asn.2013111185